This clinical trial focuses on Giant Cell Arteritis, a condition that causes inflammation in blood vessels, typically affecting people over 50 years old. The study aims to evaluate whether adding bosentan treatment for three months helps patients who are already receiving standard therapy with corticosteroids (prednisone or prednisolone) for their condition.
The treatment involves taking bosentan tablets along with either prednisone or prednisolone tablets. The maximum daily dose of bosentan will be 250 mg, while the corticosteroid dose will be up to 40 mg per day. The treatment period with bosentan lasts for 16 weeks, while the corticosteroid treatment continues for up to 52 weeks.
During the study, doctors will monitor patients to see if they can reduce their corticosteroid dose according to a planned schedule while keeping their condition under control. They will also check for any new symptoms related to Giant Cell Arteritis and assess how well patients respond to the combined treatment. The study will track patients’ progress for up to two years to understand the long-term effects of this treatment approach.
France 
